Survival for patients with aggressive pituitary tumours (APT) and pituitary carcinomas (PC)
has significantly improved following the increasing use of temozolomide (TMZ) since the first …

Purpose The purpose of this work was toinvestigate the clinicopathological characteristics at
the initial diagnosis of the pituitary tumor and at pituitary carcinoma (PC) diagnosis …

Gliomas are a heterogeneous group of brain tumours with high malignancy, for which
surgical resection remains the mainstay of treatment at present. However, the overall …

Pituitary neuroendocrine tumors (PitNETs) are the most common pituitary tumors and the
second most common brain tumors. Although the vast majority (> 90%) are benign, a small …

The current study was designed to use an epigenome-wide association approach (EWAS) to
identify potential systemic DNA methylation alterations that are associated with obesity using …

Context Temozolomide (TMZ) is endorsed as the treatment of choice in aggressive or
malignant pituitary adenomas. Objective Herein we describe a case of an aggressive …

Background Pituitary adenoma is one of the most common brain tumors. Most pituitary
adenomas are benign and can be cured by surgery and/or medication. However, some …

Current guidelines recommend temozolomide as the first-line chemotherapy for aggressive
pituitary neuroendocrine tumours. However, no clinical trials have been conducted to date …

Prolactinomas (PRLomas) constitute approximately half of all pituitary adenomas and
approximately one-fifth of them are diagnosed in males. The clinical presentation of …

Introduction Pituitary adenomas can show a tendency to grow, despite multimodal treatment.
Temozolomide (TMZ) has been used in the last 15 years in patients with aggressive pituitary …